血瘀证和活血化瘀治疗临床研究PPT.ppt

Progress of RS Study Restenosis (RS) is still the major limitation of the long-term success of coronary intervention treatment No ideal prophylactic measure so far although numerous clinical trials have been done Stents have certain effect with RS rate still between 20% and 30% Coating stents showed wonderful prospect, but the reported results were inconsistent, and the expensive price limited its application in China 再狭窄(RS)研究进展 再狭窄仍然是限制冠状动脉介入治疗远期疗效的主要因素 虽然国际上进行了大量干预再狭窄的临床试验，但目前还没有找到理想的治疗手段 支架植入术具有一定的效果，但再狭窄发生率仍然在20%～30%之间。 药物涂层支架显是有良好的前景，但研究结果报道不一，其昂贵的价格也限制了其在国内的推广应用 血府逐瘀汤Xue Fu Zhu Yu T